Scinai Immunotherapeutics (SCNI) Income towards Parent Company (2014 - 2026)

Scinai Immunotherapeutics has reported Income towards Parent Company for 13 years, with the latest figure at -$2.5 million in Q1 2026.

• Quarterly Income towards Parent Company fell 57.33% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.2 million (up 33.03% YoY) and the FY2025 annual result came in at -$38.3 million, down 18.32% from the prior year.
• Income towards Parent Company eased to -$2.5 million in Q1 2026 per SCNI's latest filing, from -$2.2 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $6.9 million in Q2 2022 and troughed at -$22.6 million in Q4 2022.
• A 5-year average of -$1.9 million and a median of -$1.6 million in 2025 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company tumbled 614.25% in 2022, then soared 241400100.0% in 2024.
• Over 5 years, Income towards Parent Company stood at -$22.6 million in 2022, then soared by 75.01% to -$5.6 million in 2023, then surged by 35.47% to -$3.6 million in 2024, then surged by 39.63% to -$2.2 million in 2025, then slipped by 12.39% to -$2.5 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$2.5 million, -$2.2 million, and -$1.6 million for Q1 2026, Q2 2025, and Q1 2025 respectively.